Section Arrow
CRGX.NASDAQ
- CARGO Therapeutics
Quotes are at least 15-min delayed:2025/01/11 18:06 EST
Last
 13.5
-0.7 (-4.93%)
Day High 
14.2075 
Prev. Close
14.2 
1-M High
17 
Volume 
265.50K 
Bid
13.45
Ask
15.85
Day Low
13.31 
Open
14.2 
1-M Low
12.17 
Market Cap 
653.59M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 14.5 
20-SMA 14.58 
50-SMA 17.09 
52-W High 33.92 
52-W Low 12.17 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-17.59/-4.09
Enterprise Value
679.86M
Balance Sheet
Book Value Per Share
8.71
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CDTConduit Pharmaceuticals0.1233+0.0413+50.37%-- 
MRSNMersana Therapeutics0.72-0.58-44.62%-- 
TNXPTonix Pharmaceuticals Holding Corp.0.2787+0.0227+8.87%-- 
ZVSAZyVersa Therapeutics1.47+0.29+24.58%0PE
SANASana Biotechnology3.66-0.64-14.88%-- 
Quotes are at least 15-min delayed:2025/01/11 18:06 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.